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Abstract
Background: This study aimed to evaluate the prevalence and alteration of hematological parameters in malaria
patients with a glucose-6-phosphate dehydrogenase (G6PD) deficiency, in the western region of Thailand, an
endemic region for malaria.
Methods: Data about patients with malaria hospitalized between 2013 and 2015 were collected. Clinical and
sociodemographic characteristics such as age and gender, diagnosis on admission, and parasitological results were
mined from medical records of the laboratory unit of the Phop Phra Hospital in Tak Province, Thailand. Venous
blood samples were collected at the time of admission to hospital to determine G6PD deficiency by fluorescence
spot test and detect malaria parasites by thick and thin film examination. Other data such as complete blood count
and parasite density were also collected and analyzed.
Results: Among the 245 malaria cases, 28 (11.4 %) were diagnosed as Plasmodium falciparum infections and 217
cases (88.6 %) were diagnosed as P. vivax infections. Seventeen (6.9 %) patients had a G6PD deficiency and 228
(93.1 %) patients did not have a G6PD deficiency. Prevalence of male patients with G6PD deficiency was higher
than that of female patients (P < 0.05, OR = 5.167). Among the patients with a G6PD deficiency, two (11.8 %) were
infected with P. falciparum, while the remaining were infected with P. vivax. Malaria patients with a G6PD deficiency
have higher monocyte counts (0.6 × 103/μL) than those without a G6PD deficiency (0.33 × 103/μL) (P < 0.05, OR =
5.167). Univariate and multivariate analyses also confirmed that malaria patients with a G6PD deficiency have high
monocyte counts. The association between G6PD status and monocyte counts was independent of age, gender,
nationality, Plasmodium species, and parasite density (P < 0.005).
Conclusion: This study showed a prevalence of G6PD deficiency in a malaria-endemic area. This study also
supported the assertion that patients with G6PD-deficient red blood cells had no protection against the P.
falciparum infection. In addition, malaria patients with a G6PD deficiency had higher monocyte counts than those
without a G6PD deficiency. These findings will help to recognize and diagnose malaria patients with a G6PD
deficiency, as well as to identify the risks and protective factors against malaria in endemic areas.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) is an en-
zyme involved in the production of the NADPH re-
quired to protect cells against oxidative stress [1]. A
G6PD deficiency is an X-linked hereditary enzyme de-
ficiency affecting approximately 400 million people
worldwide, especially in malaria-endemic areas [2]. As
a result, G6PD-deficient red blood cells (RBCs) are
more susceptible to being destroyed by oxidative
stress such as oxidative food (fava beans) and drugs
(e.g., primaquine and sulfones). Therefore, this disease
is often manifested as acute hemolytic anemia (AHA)
triggered by the intake of those stressors [3]. The
mutations of the G6PD gene result in protein variants
with different levels of enzyme activity that are asso-
ciated with a wide range of biochemical and clinical
phenotypes [4]. At present, 186 mutations affecting
the gene coding sequence have been reported, with
most of these single-base substitutions leading to
amino acid replacements [5].
Identifying G6PD deficiency in individuals prior to
treatment of malaria is essential to protect patients from
hemolytic reactions because malaria and G6PD defi-
ciency share similar geographical distributions. Treat-
ment of malaria patients with antimalarial drugs, such
as primaquine or other 8-aminoquinolines, may be asso-
ciated with potential hemolytic anemia [6]. The most re-
cent study showed that adding primaquine to malaria
treatments reduces gametocyte prevalence in patients
and may prevent people from transmitting malaria [7].
It is also postulated that G6PD deficiencies have become
more frequent because G6PD-deficient variants confer
some protection or resistance against malaria caused by
the species P. falciparum and P. vivax [8]. The protect-
ive role of a G6PD deficiency against infection with P.
falciparum malaria has also been supported by various
case–control studies [9–11].
The Thailand-Myanmar border area is in the western
part of Thailand. It is the most common destination for
ethnic minorities from Myanmar who migrate to
Thailand for agricultural work. The Thai-Myanmar
border is also a malaria-endemic area and is often de-
scribed as an ‘epicenter’ of drug-resistant malaria. This
study aimed to identify the prevalence of G6PD defi-
ciency among patients with malaria and the alteration of
hematological parameters in patients with a G6PD
deficiency.
Methods
This study gathered data about patients diagnosed
with a malaria infection who have a G6PD deficiency,
from the laboratory unit of the Phop Phra Hospital in
Tak Province, Thailand, between January 2013 and
April 2015. The data were collected by examining the
history of malaria patients and the results of G6PD
deficiency tests. Other general characteristics about
the patients such as age, gender, and nationality were
also collected.
The fluorescence spot test (R&D Diagnostics, Aghia
Paraskevi, Greece) was conducted to detect the presence
or absence of a G6PD deficiency, with the results indi-
cating ‘heterozygous or homozygous G6PD deficiency’
when there wasn’t any signal from the test. Those with
fluorescent signals were classified as ‘normal.’ The
laboratory data collected comprised complete blood
count (CBC) using the BC-5200 Haematology Analyzer
(Mindray, Nanshan, Shenzhen, China). This included
white blood cell (WBC) count and differential count,
RBC count, hemoglobin (Hb) level, platelet counts,
mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), and red cell distribution width
(RDW). A malaria test was performed by staining a
blood film with Giemsa stain. The microscopic
abnormality of blood in a smear was detected using a
haematology analyzer, and laboratory technicians
determined the presence or absence of malaria under
a light microscope. The parasite density was also
determined and defined as low parasitemia (1–100
parasites/100 oil fields), moderate parasitemia (1–10
parasites/1 oil fields), and high parasitemia (>100 par-
asites/1 oil field).
Data analysis was performed to show frequency,
percentage, and central tendency of patients with
malaria. Tests for the homogeneity of data were per-
formed to identify a suitable statistical analysis. Com-
parisons of proportions were based on the chi-square
test or Fisher’s exact test. Tests for the comparison of
continuous variables in different groups were based
on the independent t-test or Mann–Whitney U test.
To test whether there was an association between
G6PD status and hematological parameters, a logistic
regression was used to adjust for age, gender,
nationality, type of malaria, and parasite density. All
tests were performed using the SPSS software version
11.5 for Windows (SPSS Inc., Chicago, IL, USA), with P-
values less than 0.05 considered statistically significant.
The protocol of this study was approved by the
Phop Phra Hospital and the Ethical Clearance
Committee on Human Rights Related to Researches
Involving Human Subjects of Walailak University,
Thailand.
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Results
From January 2013 to April 2015, 245 individuals were
diagnosed with a malaria infection at the Phop Phra
Hospital, Thailand. Of those, 17 (6.9 %) were diagnosed
with a G6PD deficiency. The median age was 20 years in
patients with a G6PD deficiency and 19 years in patients
without a G6PD deficiency. One hundred and fifty cases
(61.2 %) were male and 95 (38.8 %) were female. One
hundred and thirty cases (53.1 %) were of Thai national-
ity and 115 (46.9 %) were Burmese. No significant differ-
ences were observed between the patients’ age,
nationality, or G6PD status in patients with a G6PD
deficiency and patients without a G6PD deficiency (P >
0.05) (see Table 1). Twenty-eight cases (11.4 %) were in-
fected with P. falciparum, while the remaining 217 cases
(88.6 %) were infected with P. vivax. Of the patients with
a G6PD deficiency, two cases (11.8 %) were infected with
P. falciparum and 15 cases (88.2 %) were infected with
P. vivax.
Of the patients without a G6PD deficiency, 26 (11.4 %)
were infected with P. falciparum and 202 cases (88.6 %)
were infected with P. vivax. The percentage of P. falcip-
arum infected and G6PD-deficient individuals and P. fal-
ciparum infected non-G6PD-deficient individuals was
the same (~11 %). This clearly shows that having a
G6PD deficiency does not protect against the P. falcip-
arum infection. A significant association was observed
between gender and G6PD status in patients with mal-
aria (P < 0.05, OR = 5.167), with the incidence of G6PD
deficiency being higher in males than in females. In this
study, the absolute monocyte count was higher in pa-
tients with a G6PD deficiency (mean = 0.6 × 103/μL) than
those without a G6PD deficiency (mean = 0.33 × 103/μL)
(P < 0.05). However, no significant differences were ob-
served between G6PD status and other hematological
parameters, such as WBC count, neutrophil count, eo-
sinophil count, basophil count, lymphocyte count, RBC
count, Hb level, platelet counts, MCV, MCH, and
MCHC (P > 0.05) (see Table 2). After adjusting for these
parameters, a univariate analysis between G6PD status
and hematological parameters showed that the absolute
monocyte count was significantly different between
those with and without a G6PD deficiency (P < 0.05) (see
in Table 3). In addition, gender was significantly associ-
ated with G6PD status (P < 0.05), a multivariate analysis
also showed that the difference in monocyte count be-
tween the two groups was still significant (P < 0.05).
Among the patients with a G6PD deficiency, 11 cases
Table 1 General characteristics of the study participants
Demographic G6PD status P-value OR
(95 % CI)G6PD def. Normal
Age (median, range) 20 (12–52) 19 (0–71) 0.364* NA
Male, n (%) 15 (88.2 %) 135 (59.2 %) 0.019** 5.167
Female, n (%) 2 (11.8 %) 93 (40.8 %)
Thai, n (%) 8 (47.1 %) 122 (53.5 %) 0.625** 0.772
Burmese, n (%) 9 (52.9 %) 106 (46.5 %)
*Comparison of the two groups using the Mann–Whitney U test
**Comparison of the two groups using the Fisher’s exact test
Table 2 Hematological parameters of patients with malaria
infection
Parameter G6PD def. Normal P-
valueMean ± SD Mean ± SD
Leukocyte (×103/μL) 6.85 ± 1.37 6.21 ± 2.31 0.058
Neutrophil (×103/μL) 4.77 ± 1.41 4.33 ± 1.98 0.929
Lymphocyte (×103/μL) 1.2 ± 0.63 1.27 ± 0.9 0.313
Monocyte (×103/μL) 0.6 ± 0.43 0.33 ± 0.28 0.013*
Eosinophil (×103/μL) 0.2 ± 0.28 0.2 ± 0.75 0.552
Basophil (×103/μL) 0.08 ± 0.06 0.07 ± 0.06 0.873
RBCs (×106/μL) 4.5 ± 0.85 4.62 ± 0.72 0.845
Hb (g/dL) 12.16 ± 2.4 12.12 ± 1.96 0.862
Hematocrit (%) 36.76 ± 6.99 35.93 ± 5.55 0.668
MCV (fL) 82.02 ± 7.99 77.99 ± 8.7 0.093
MCH (pg/cell) 27.13 ± 2.9 26.36 ± 3.59 0.48
MCHC (g/dL) 33.08 ± 1.63 33.81 ± 1.31 0.069
RDW (%) 12.38 ± 1.86 12.7 ± 1.37 0.026*
Platelet (×103/μL) 98.24 ± 71.81 83.82 ± 50.27 0.539
*P-value determined using the Mann–Whitney U test
Table 3 Univariate and multivariate analyses of G6PD status
and hematological parameters adjusted by age, type of









P. falciparum/P. vivax −0.035 0.964
Nationality 0.258 0.608
Parasite density 0.167 0.751





P. falciparum/P. vivax 0.131 0.877
Parasite density 0.412 0.491
Constant 0.290 0.931
*unstandardized variables
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(64.7 %) had a lower parasite density and six (35.3 %)
had a moderate parasite density. Among the patients
without a G6PD deficiency, 156 (68.45 %) had low para-
sitemia, 66 (28.95 %) had moderate parasitemia, and six
(2.6 %) had high parasitemia.
Discussion
A previous study showed that 20.8 % of the Thai and
Burmese populations who reside in malaria-endemic
areas (western, northern, northeastern, southern, east-
ern, and central regions) of Thailand are G6PD deficient
[12]. This indicates that malaria and G6PD deficiency
share similar geographical distributions. This study
showed that 6.9 % of malaria-infected patients were di-
agnosed with a G6PD deficiency, which is lower than re-
ported by previous studies conducted in southeast Iran
(27 %) [13], Cambodia (13.9 %) [14], and southwest
Ethiopia (7.3 %) [15]. However, it was higher than that
reported in Eastern Indonesia (5.1 %) [16] and the
Brazilian Amazon (4.5 %) [17]. A recent study conducted
in the Thailand-Myanmar border area indicated that the
overall frequency of G6PD deficiency determined using
the fluorescence spot test was 13.7 %. Of those patients,
almost 90 % had the Mahidol variant (487G > A) geno-
type, whereas the remaining subjects had the Chinese-4
(392G > T), Viangchan (871G > A), Açores (595A > G),
Seattle (844G > C), or Mediterranean (563C > T) variants
[18]. Another study focusing on the Thailand-Myanmar
border area also found a high frequency of G6PD Mahi-
dol (96.2 %; 38.1 % in the Thai population and 96.2 % in
the Burmese population) [12]. The prevalence of G6PD
deficiency in other areas of Thailand such as in Chiang
Mai province was found to be lower (4 %) than along
the Thailand-Myanmar border [19].
A significant association was observed between gender
and G6PD status in patients with malaria (P < 0.05, OR
= 5.167), with the incidence of G6PD deficiency being
higher in males than in females. This is similar to the
findings of other studies [14, 20], and is likely due to
G6PD deficiency being an X-linked hereditary disease,
with the male tending to be at greater risk than the fe-
male as the male has only one X-chromosome. Hemizy-
gous males and homozygous normal females are most
and least commonly affected, respectively. Heterozygous
females have mixed G6PD normal and deficient RBCs,
and their total G6PD enzyme activity and susceptibility
to hemolysis depends on the balance between the ex-
pression of the normal and abnormal X-chromosomes
[21]. A previous study reported that mutation in the
G6PD gene gives boys substantial protection against se-
vere malaria. The reason for this difference in protection
is not clear, as it is not known how malaria parasites are
affected by RBCs that lack G6PD activity [22]. Some epi-
demiological and clinical studies have shown that
individuals who are heterozygous and/or hemi-/homozy-
gous are at lower risk of developing severe malaria or
succumbing to it [23]. These findings are defined as the
‘malaria/G6PD hypothesis’ [24], but the mechanism of
protection remains under discussion.
The absolute monocyte count was higher in patients
with a G6PD deficiency than those without a G6PD defi-
ciency. The main cause of a high monocyte count is sup-
ported by previous studies that indicate that a certain
percentage of circulating phagocytic cells containing
hemozoin is strongly associated with parasitemia and se-
verity of disease in malaria patients [25, 26]. Hemozoin-
loaded monocytes are also functionally impaired as they
do not produce oxidative burst and are unable to repeat
the phagocytic process [27, 28]. In addition, G6PD-
deficient red cells will lyse upon oxidative stress pro-
duced by the parasites, and thus send signals to be
phagocytosed more than normal red cells. This will gen-
erally explain why malaria is only mild or moderate and
not severe in patients with a G6PD deficiency.
Among the patients with a G6PD deficiency, 11 cases
(64.7 %) had a lower parasite density and six (35.3 %)
had a moderate parasite density. Among the patients
without a G6PD deficiency, 156 (68.45 %) had low para-
sitemia, 66 (28.95 %) had moderate parasitemia, and six
(2.6 %) had high parasitemia. This means that patients
with a G6PD deficiency exhibit low and moderate para-
sitemia, whereas patients without a G6PD deficiency ex-
hibit low, moderate, and high parasitemia. This is likely
caused by the G6PD deficiency protecting against mal-
aria, however, this study cannot conclude the role of
G6PD deficiency against malaria because only a small
number of patients with a G6PD deficiency was re-
cruited and studied. Previous studies have also detected
a lower parasite count in G6PD-deficient patients [10,
29, 30].
Awareness of high prevalence of G6PD deficiency was
from potential hemolytic reactions due to treatment of
malaria with primaquine. Primaquine is the only gener-
ally available antimalarial drug that prevents relapse in
vivax and ovale malaria, and the only one that prevents
potent gametocytocidal activity in falciparum malaria.
Primaquine can cause dose-dependent AHA that is
greater in more severely deficient G6PD variants; AHA
can be potentially life threatening, but primaquine-
related deaths are very rare [31, 32]. This toxicity is a
significant public health concern because G6PD defi-
ciency affects approximately 400 million people world-
wide who live mostly in malaria-endemic countries,
where the median G6PD deficiency allele prevalence was
8 % [33]. Aside from G6PD deficiency, patients with
homozygous HbEE have a higher chance of P. falcip-
arum infection compared to those with normal HbAA
(odds ratio [OR] = 5.0) [34].
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In addition to treatment of malaria with primaquine,
drug resistance has remained the greatest challenge to
malaria control. Despite a large number of antimalarial
drugs available, there is no perfect drug; all have limita-
tions such as poor compliance, side effects, toxicity,
and/or resistance. The support from international orga-
nizations and governments of some endemic countries
should be optimally exploited in various approaches to
drug research and development in order to overcome
the burden of malaria [35].
This study had several limitations: a small number of
patients with a G6PD deficiency; could not obtain data
about diseases affecting hematological parameters; and
the fluorescent spot test is not a confirmatory test for
G6PD. However, the results of this study still provide valu-
able information relating to G6PD deficiency in patients
infected with malaria in endemic regions of Thailand.
Conclusion
This study showed a prevalence of G6PD deficiency, which
becomes apparent from potential hemolytic reactions due
to treatment of malaria with primaquine. The study also
supported the notion that patients with G6PD deficient-
RBCs had no protection against P. falciparum infection. In
addition, malaria patients with a G6PD deficiency had
higher monocyte counts than those without a G6PD defi-
ciency, and this was independent of age, gender, nationality,
Plasmodium species, and parasite density. These findings
will help to recognize and diagnose malaria patients with a
G6PD deficiency, as well as to identify the risks and pro-
tective factors against malaria in endemic areas.
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